1. Volume 15, Issue 8, Pages 1005-1013 (December 2012)
Cost-Effectiveness of Using a Molecular Diagnostic Test to Improve Preoperative Diagnosis of Thyroid Cancer 
Mehdi Najafzadeh, PhD, Carlo A. Marra, PharmD, PhD, Larry D. Lynd, PhD, Sam M. Wiseman, MD, FRCSC 
Value in Health 
Volume 15, Issue 8, Pages (December 2012)
DOI: /j.jval
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Incremental cost and effectiveness for different sensitivity and specificity of DX test. DX, diagnostic; QALY, quality-adjusted life-year.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Net monetary benefit of DX test for different levels of cost per DX test. Incremental net monetary benefits were calculated on the basis of λΔQALY − ΔC, where Δ QALY and ΔC are the incremental QALYs and incremental costs of DX relative to NoDX, respectively, and λ is society's willingness to pay for an additional QALY gained, which was assumed to be $50,000. DX, diagnostic; QALY, quality-adjusted life-year.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Results of univariate sensitivity analysis. AUS, atypia or follicular lesion of undetermined significance; diag, diagnosis; FN, follicular neoplasm; prob, probability; RLNI, recurrent laryngeal nerve injury.
Value in Health  , DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions